News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Upgrades 2025 full-year CDMO sales and margin outlook
Subscribe To Our Newsletter & Stay Updated
